ClinicalTrials.gg
RecruitingNCT07758101Updated Nov 17, 2026

A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease

A Phase 1 interventional study of SHR-7590 and Placebo in Moderate-to-severe Inflammatory Bowel Disease, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 17, 2026Now RecruitingPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with moderate-to-severe inflammatory bowel disease.

02

Conditions studied

  • Moderate-to-severe Inflammatory Bowel Disease
03

In context

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Part 1

  • Voluntarily signed the form
  • Age from 18 to 55 years old
  • Body weight ≥45 kg, (BMI) 18-26 kg/m2
  • Normal or clinically insignificant vital signs, physical examination, laboratory examination and other examinations
  • Adopt efficient measures

Part 2:Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease)

Participants must meet all of the following criteria to be included in this study:

  1. Age at signing the informed consent form is ≥ 18 years and ≤ 75 years (inclusive of both ends), regardless of gender.
  2. Body Mass Index (BMI) at screening is ≥ 18 kg/m².
  3. At the time of the first administration, the participant has been diagnosed with ulcerative colitis or Crohn's disease for at least 90 days, and this has been confirmed by endoscopic examination at the screening visit.
  4. The investigator believes that the participant has inadequate response, loss of response, or intolerance to conventional treatments (such as oral 5-ASA, or (such as azathioprine, 6-mercaptopurine), or ).
  5. If the participant is currently receiving any of the following UC or CD treatments, they should receive a stable dose of medication within the specified time frame. The specific requirements are as follows:

    • Oral 5-ASA (mesalazine) or sulfasalazine (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period), and/or
    • Oral corticosteroids (prednisolone ≤ 20 mg/day or equivalent) (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period).
  6. Participants voluntarily sign the informed consent before any procedures related to the study commence, enabling smooth communication with the researchers, understanding and willing to strictly adhere to the requirements of this clinical study protocol to complete the research.
  7. Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until the end of the safety follow-up period, have no plans for pregnancy, sperm donation, or egg donation, and voluntarily take effective contraceptive measures (including the partner, as detailed in Appendix 1). Female participants during the screening period and before the first administration must have a negative pregnancy test result and must be non-lactating.

    ---

    Part of participants with moderate to severe ulcerative colitis:

    Participants must meet all of the following criteria to enter this study:

  8. Participants with active ulcerative colitis with a modified 9-point Mayo score of 4 to 9 and an endoscopic item score of 2 to 3, and with a bleeding item score of at least 1.

    ---

    Part of participants with moderate to severe Crohn's disease:

    Participants must meet all of the following criteria to enter this study:

  9. Baseline CDAI score of 220 to 450, endoscopic SES-CD score (excluding the presence of stenosis) of ≥ 6 points (or isolated ileal disease participants ≥ 4 points), and at least an average daily stool frequency (SF) of 4 timesand/or an average daily abdominal pain (AP) score of ≥ 2 points.

Exclusion criteria

Exclusion Criteria:

- Part 1

  • Suspected allergy to the study drug or any component of the study drug
  • Any clinical disease or any other disease that could interfere with the test results
  • Had a history of malignant tumor
  • Had an opportunistic infection within 6 months before screening
  • Acute infection with constitutional symptoms within 4 weeks before baseline
  • Participants who participated in any drug or device clinical trial within 3 months before screening
  • Use of any drug within 1 month before the use of the drug
  • Patients who had used or anti-interleukin antibody drugs within 6 months before screening
  • Had major trauma or major surgery within 6 months before screening, or were scheduled to undergo surgery during the trial
  • History of blood donation within 1 month before screening, or severe blood loss

Part 2:

Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease) who have any of the following conditions are not eligible to participate in this study (common section):

1. Medical History or Comorbidities

1. Participants who have been diagnosed with ulcerative colitis or Crohn's disease and are on the initial treatment (without previous treatment).

2. During the screening endoscopy, participants have a history of gastrointestinal dysplasia (atypical hyperplasia)/cancer or atypical hyperplasia/cancer. Exclude complete low-grade dysplasia that has been completely removed.

3. Have evidence of pathogenic intestinal infection. 4. Currently or previously have:

  • Had a major clinical infection (such as requiring hospitalization or parenteral antimicrobial treatment or opportunistic infection) within 1 month before baseline.
  • Had two or more episodes of herpes zoster or disseminated herpes zoster.
  • Any other infection history that the investigator considers may be exacerbated by participating in this study.
  • Had any infection requiring antimicrobial treatment within 2 weeks before screening.

    2. Prior Treatments and Clinical Studies 5. Participants who received azathioprine/6-mercaptopurine, methotrexate, thalidomide treatment within 2 weeks before baseline.

    6. Participants who received cyclosporine, mycophenolate mofetil, tacrolimus or intravenous within 8 weeks before baseline.

    7. Participants who received interferon treatment. 8. Participants who received rectal corticosteroid preparations or 5-ASA treatment within 2 weeks before baseline.

    9. Participants who have participated in any clinical study of drugs (including investigational vaccines) or medical devices within 3 months before baseline or within 5 half-lives (whichever is longer).

    3. Important Medical History or Underlying Diseases Affecting Safety

    1. Participants who have a history of lymphocytic proliferative diseases, including lymphoma or symptoms and signs of potential lymphoproliferative disorders.
    2. Participants who have had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening visit, except for treated skin squamous cell carcinoma or basal cell carcinoma or in situ cervical cancer.
    3. Participants who have had moderate to severe congestive heart failure history ( cardiac function classification ≥ III) within 3 months before screening, or have had cardiovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study.
    4. Have active tuberculosis (TB) or latent tuberculosis infection
    5. Positive for surface antigen (HBsAg), antibody (HIV), syphilis antibody test, and anti- virus (HCV) antibody test; if HBsAg is negative, but the hepatitis B core antibody (HBcAb) is positive and the hepatitis B viral deoxyribonucleic acid (HBV DNA) is positive or exceeds the value.
    6. Suffering from severe, progressive, or uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane (such as severe athlete's foot), and other conditions that the investigator considers not suitable for participation in this trial.

    4. Laboratory Tests and Abnormalities

    1. (AST) or alanine aminotransferase (ALT) ≥ 3 × ULN.
    2. Total ≥ 1.5 × ULN.
    3. Serum creatinine > 2.0 mg/dl (177 μmol/L).
    4. \< 85.0 g/L (male) or \< 80.0 g/L (female).
    5. White blood cell count \< 3.0 × 10⁹/L.
    6. \< 1.5 × 10⁹/L.
    7. count \< 100 × 10⁹/L.
    8. 12-lead electrocardiogram examination indicates abnormalities that may affect the safety of the participant, including but not limited to acute myocardial ischemia, myocardial infarction, severe arrhythmia or significant prolongation. Refer to Appendix 3 for detailed ECG exclusion criteria.

    5. General Conditions

    1. Pregnant or lactating women, or those with a positive hCG test.
    2. Allergic to the study drug or any component of the study drug.
    3. Within one year before screening, there is a history of alcohol abuse or illegal drug abuse.
    4. Within 12 weeks before the first administration, received attenuated , or plan to receive attenuated live vaccines during the study, or participated in a vaccine clinical trial within 12 weeks before the first administration.
    5. Within 8 weeks before the first administration, donated approximately 500 mL of blood or has a blood donation plan during the study.
    6. The participant is unable to tolerate or refuses the relevant operations of this study, including endoscopic examination and during the study.
    7. The investigator judges that there are situations that affect the safety and efficacy evaluation of the study drug.

      ---

      Part of participants with severe ulcerative colitis:

      Participants with any of the following conditions cannot be enrolled in this study:

    6. UC-specific Exclusions

    1. Participants with clinical manifestations diagnosed as undetermined colitis or suggesting Crohn's disease.

    2. Participants with ulcerative colitis, limited to proctitis (distal ≤ 15 cm). 3. Participants showing clinical symptoms of ischemic colitis, fulminant colitis or toxic megacolon.

    4. Participants who have previously undergone surgical treatment for ulcerative colitis or who may require surgical treatment during the study period.

Participants with moderate to severe Crohn's disease:

Any of the following conditions must be absent for a participant to be eligible for this study:

7. CD-specific Exclusions

  1. Participants diagnosed with indeterminate colitis or presenting symptoms suggestive of ulcerative colitis.
  2. Currently known to have Crohn's disease complications, such as abdominal or perianal abscesses, symptomatic intestinal stenosis, the absence of more than 2 of the 5 intestinal segments (terminal ileum, right colon, transversecolon, sigmoid colon and left colon, rectum), fulminant colitis, toxic megacolon, or any manifestations that may require surgical intervention during the study period.
  3. Having an ostomy or ileoanal pouch.
  4. Having diseases that may interfere with drug absorption, including but not limited to short bowel or short bowel syndrome.
  5. Having undergone surgical resection within 3 months prior to baseline, or having a history of 3 intestinal resections.
  6. Participants who may require surgical treatment during the study period.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Part1:Dose Level:A

    Subject will receive SHR-7590 at dose level A. Subject will receive placebo at dose level A.

    Drug: SHR-7590 · Drug: Placebo

  • Experimental
    Part1:Dose Level:B

    Subject will receive SHR-7590 at dose level B. Subject will receive placebo at dose level B.

    Drug: SHR-7590 · Drug: Placebo

  • Experimental
    Part1:Dose Level:C

    Subject will receive SHR-7590 at dose level C. Subject will receive placebo at dose level C.

    Drug: SHR-7590 · Drug: Placebo

  • Experimental
    Part1:Dose Level:D

    Subject will receive SHR-7590 at dose level D. Subject will receive placebo at dose level D.

    Drug: SHR-7590 · Drug: Placebo

  • Experimental
    Part1:Dose Level:E

    Subject will receive SHR-7590 at dose level E. Subject will receive placebo at dose level E.

    Drug: SHR-7590 · Drug: Placebo

  • Experimental
    Part2: Dose Level:A

    Subjects with Ulcerative Colitis will receive SHR-7590 at dose level A

    Drug: SHR-7590

  • Experimental
    Part2: Dose Level:B

    Subjects with Ulcerative Colitis may receive SHR-7590 at dose level B(optional)

    Drug: SHR-7590

  • Experimental
    Part2: Dose Level: C

    Subjects with Crohn's Disease will receive SHR-7590 at dose level C

    Drug: SHR-7590

  • Experimental
    Part2: Dose Level: D

    Subjects with Crohn's Disease may receive SHR-7590 at dose level D (optional)

    Drug: SHR-7590

Interventions

  • DrugSHR-7590

    SHR-7590

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Part1: Adverse events

    Time frame: From ICF signing date to Day 281

  2. Part1: Serious adverse events

    Time frame: From ICF signing date to Day 281

  3. Part2: Adverse events

    Time frame: From ICF signing date to Day 393

  4. Part2: Serious adverse events

    Time frame: From ICF signing date to Day 393

  5. Part2: Results of 12-lead electrocardiography

    Time frame: From ICF signing date to Day 393

Secondary outcomes

  1. Part1:Maximum observed concentration of SHR-7590 (Cmax)

    Time frame: From 0 hour date to Day 281

  2. Part1: Time to maximum observed concentration (Tmax) of SHR-7590

    Time frame: 0 hour to Day 281

  3. Part1: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590

    Time frame: 0 hour to Day 281

  4. Part1: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)

    Time frame: 0 hour to Day 281

  5. Part1: Half-life (T1/2) of SHR-7590

    Time frame: 0 hour to Day 281

  6. Part1: Clearance (CL) of SHR-7590

    Time frame: 0 hour to Day 281

  7. Part1: Apparent clearance(CL/F)of SHR-7590

    Time frame: 0 hour to Day 281

  8. Part1: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590

    Time frame: 0 hour to Day 281

  9. Part2: Maximum observed concentration of SHR-7590 (Cmax)

    Time frame: From 0 hour date to Day 393

  10. Part2: Time to maximum observed concentration (Tmax) of SHR-7590

    Time frame: 0 hour to Day 393

  11. Part2: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590

    Time frame: 0 hour to Day 393

  12. Part2: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)

    Time frame: 0 hour to Day 393

  13. Part2: Half-life (T1/2) of SHR-7590

    Time frame: 0 hour to Day 393

  14. Part2: Clearance (CL) of SHR-7590

    Time frame: 0 hour to Day 393

  15. Part2: Apparent clearance(CL/F)of SHR-7590

    Time frame: 0 hour to Day 393

  16. Part2: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590

    Time frame: 0 hour to Day 393

  17. Part2: Immunogenicity of SHR-7590 in healthy participants and patients with moderate-to-severe ulcerative colitis.

    Time frame: 0 hour to Day 393

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangzhou 510080, China
    Recruiting
    • Minhu Chen · Principal investigator
    • Baili Chen · Principal investigator
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Bo Jiang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jan 2027 → Mar 2028 and completion Dec 2027 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 11, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Mar 31, 2028was Jan 2027
CompletionEst.
Apr 28, 2029was Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
1 site added. The Second Affiliated Hospital Zhejiang University School of Medicine is now Recruiting
Show site
  • The First Affiliated Hospital of Sun Yat-sen University · Guangzhou, China
across 2 updates, Sep 25, 2026 – Nov 17, 2026
Primary completion
Jan 2027→Mar 31, 2028
Nov 17, 2026
Study completion
Dec 2027→Apr 28, 2029
Nov 17, 2026
Enrollment
64→88
Sep 25, 2026
Eligibility
Maximum age 55 Years→75 Years; Criteria largely rewritten (73 changes)
What changed in the criteria
Inclusion criteria
  • AddedPart 2:Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease)
  • AddedParticipants must meet all of the following criteria to be included in this study:
  • AddedAge at signing the informed consent form is ≥ 18 years and ≤ 75 years (inclusive of both ends), regardless of gender.
  • AddedBody Mass Index (BMI) at screening is ≥ 18 kg/m².
  • AddedAt the time of the first administration, the participant has been diagnosed with ulcerative colitis or Crohn's disease for at least 90 days, and this has been confirmed by endoscopic examination at the screening visit.
  • AddedThe investigator believes that the participant has inadequate response, loss of response, or intolerance to conventional treatments (such as oral 5-ASA, or immunosuppressants (such as azathioprine, 6-mercaptopurine), or corticosteroids).
  • AddedIf the participant is currently receiving any of the following UC or CD treatments, they should receive a stable dose of medication within the specified time frame. The specific requirements are as follows:
  • AddedOral 5-ASA (mesalazine) or sulfasalazine (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period), and/or
  • AddedOral corticosteroids (prednisolone ≤ 20 mg/day or equivalent) (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period).
  • AddedParticipants voluntarily sign the informed consent before any procedures related to the study commence, enabling smooth communication with the researchers, understanding and willing to strictly adhere to the requirements of this clinical study protocol to complete the research.
  • AddedFemale participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until the end of the safety follow-up period, have no plans for pregnancy, sperm donation, or egg donation, and voluntarily take effective contraceptive measures (including the partner, as detailed in Appendix 1). Female participants during the screening period and before the first administration must have a negative pregnancy test result and must be non-lactating.
  • Added---
  • AddedPart of participants with moderate to severe ulcerative colitis:
  • AddedParticipants must meet all of the following criteria to enter this study:
  • AddedParticipants with active ulcerative colitis with a modified 9-point Mayo score of 4 to 9 and an endoscopic item score of 2 to 3, and with a bleeding item score of at least 1.
  • Added---
  • AddedPart of participants with moderate to severe Crohn's disease:
  • AddedParticipants must meet all of the following criteria to enter this study:
  • AddedBaseline CDAI score of 220 to 450, endoscopic SES-CD score (excluding the presence of stenosis) of ≥ 6 points (or isolated ileal disease participants ≥ 4 points), and at least an average daily stool frequency (SF) of 4 timesand/or an average daily abdominal pain (AP) score of ≥ 2 points.
Exclusion criteria
  • AddedPart 2:
  • AddedParticipants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease) who have any of the following conditions are not eligible to participate in this study (common section):
  • Added1. Medical History or Comorbidities
  • Added1. Participants who have been diagnosed with ulcerative colitis or Crohn's disease and are on the initial treatment (without previous treatment).
  • Added2. During the screening endoscopy, participants have a history of gastrointestinal dysplasia (atypical hyperplasia)/cancer or atypical hyperplasia/cancer. Exclude complete low-grade dysplasia that has been completely removed.
  • Added3. Have evidence of pathogenic intestinal infection. 4. Currently or previously have:
  • AddedHad a major clinical infection (such as requiring hospitalization or parenteral antimicrobial treatment or opportunistic infection) within 1 month before baseline.
  • AddedHad two or more episodes of herpes zoster or disseminated herpes zoster.
  • AddedAny other infection history that the investigator considers may be exacerbated by participating in this study.
  • AddedHad any infection requiring antimicrobial treatment within 2 weeks before screening.
  • Added2. Prior Treatments and Clinical Studies 5. Participants who received azathioprine/6-mercaptopurine, methotrexate, thalidomide treatment within 2 weeks before baseline.
  • Added6. Participants who received cyclosporine, mycophenolate mofetil, tacrolimus or intravenous corticosteroids within 8 weeks before baseline.
  • Added7. Participants who received interferon treatment. 8. Participants who received rectal corticosteroid preparations or 5-ASA treatment within 2 weeks before baseline.
  • Added9. Participants who have participated in any clinical study of drugs (including investigational vaccines) or medical devices within 3 months before baseline or within 5 half-lives (whichever is longer).
  • Added3. Important Medical History or Underlying Diseases Affecting Safety
  • AddedParticipants who have a history of lymphocytic proliferative diseases, including lymphoma or symptoms and signs of potential lymphoproliferative disorders.
  • AddedParticipants who have had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening visit, except for treated skin squamous cell carcinoma or basal cell carcinoma or in situ cervical cancer.
  • AddedParticipants who have had moderate to severe congestive heart failure history (NYHA cardiac function classification ≥ III) within 3 months before screening, or have had cardiovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study.
  • AddedHave active tuberculosis (TB) or latent tuberculosis infection
  • AddedPositive for hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibody (HIV), syphilis antibody test, and anti-hepatitis C virus (HCV) antibody test; if HBsAg is negative, but the hepatitis B core antibody (HBcAb) is positive and the hepatitis B viral deoxyribonucleic acid (HBV DNA) is positive or exceeds the upper limit of the normal value.
  • AddedSuffering from severe, progressive, or uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane (such as severe athlete's foot), and other conditions that the investigator considers not suitable for participation in this trial.

…and 33 more changes, on the record history on ClinicalTrials.gov ↗

Nov 17, 2026
Interventions
Arm changed Dose Level:A→Part1:Dose Level:A; Dose Level:B→Part1:Dose Level:B; Dose Level:C→Part1:Dose Level:C; Dose Level:D→Part1:Dose Level:D; Dose Level:E→Part1:Dose Level:E. Arms added: Part2: Dose Level:A·Part2: Dose Level:B·Part2: Dose Level: C·Part2: Dose Level: D
Nov 17, 2026
Primary outcomes
2 edited, 3 added
What changed in the outcomes
  • EditedPart1: Adverse eventsTime frame: From ICF signing date to Day 281
  • EditedPart1: Serious adverse eventsTime frame: From ICF signing date to Day 281
  • AddedPart2: Adverse eventsTime frame: From ICF signing date to Day 393
  • AddedPart2: Serious adverse eventsTime frame: From ICF signing date to Day 393
  • AddedPart2: Results of 12-lead electrocardiographyTime frame: From ICF signing date to Day 393
Nov 17, 2026
Secondary outcomes
8 edited, 9 added
What changed in the outcomes
  • EditedPart1:Maximum observed concentration of SHR-7590 (Cmax)Time frame: From 0 hour date to Day 281
  • EditedPart1: Time to maximum observed concentration (Tmax) of SHR-7590Time frame: 0 hour to Day 281
  • EditedPart1: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590Time frame: 0 hour to Day 281
  • EditedPart1: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)Time frame: 0 hour to Day 281
  • EditedPart1: Half-life (T1/2) of SHR-7590Time frame: 0 hour to Day 281
  • EditedPart1: Clearance (CL) of SHR-7590Time frame: 0 hour to Day 281
  • EditedPart1: Apparent clearance(CL/F)of SHR-7590Time frame: 0 hour to Day 281
  • EditedPart1: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590Time frame: 0 hour to Day 281
  • AddedPart2: Maximum observed concentration of SHR-7590 (Cmax)Time frame: From 0 hour date to Day 393
  • AddedPart2: Time to maximum observed concentration (Tmax) of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)Time frame: 0 hour to Day 393
  • AddedPart2: Half-life (T1/2) of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Clearance (CL) of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Apparent clearance(CL/F)of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590Time frame: 0 hour to Day 393
  • AddedPart2: Immunogenicity of SHR-7590 in healthy participants and patients with moderate-to-severe ulcerative colitis.Time frame: 0 hour to Day 393
Nov 17, 2026
Title
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-Severe Ulcerative Colitissevere Inflammatory Bowel Disease
Sep 25, 2026
Show all 2 updates
  1. Nov 17, 2026
    1 site added
    Show site
    • The First Affiliated Hospital of Sun Yat-sen University · Guangzhou, China
    Primary completion Jan 2027→Mar 31, 2028
    Study completion Dec 2027→Apr 28, 2029
    Eligibility Maximum age 55 Years→75 Years; Criteria largely rewritten (73 changes)
    What changed in the criteria
    Inclusion criteria
    • AddedPart 2:Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease)
    • AddedParticipants must meet all of the following criteria to be included in this study:
    • AddedAge at signing the informed consent form is ≥ 18 years and ≤ 75 years (inclusive of both ends), regardless of gender.
    • AddedBody Mass Index (BMI) at screening is ≥ 18 kg/m².
    • AddedAt the time of the first administration, the participant has been diagnosed with ulcerative colitis or Crohn's disease for at least 90 days, and this has been confirmed by endoscopic examination at the screening visit.
    • AddedThe investigator believes that the participant has inadequate response, loss of response, or intolerance to conventional treatments (such as oral 5-ASA, or immunosuppressants (such as azathioprine, 6-mercaptopurine), or corticosteroids).
    • AddedIf the participant is currently receiving any of the following UC or CD treatments, they should receive a stable dose of medication within the specified time frame. The specific requirements are as follows:
    • AddedOral 5-ASA (mesalazine) or sulfasalazine (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period), and/or
    • AddedOral corticosteroids (prednisolone ≤ 20 mg/day or equivalent) (with a stable dose maintained at least 2 weeks before baseline and a constant dose throughout the entire treatment period).
    • AddedParticipants voluntarily sign the informed consent before any procedures related to the study commence, enabling smooth communication with the researchers, understanding and willing to strictly adhere to the requirements of this clinical study protocol to complete the research.
    • AddedFemale participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until the end of the safety follow-up period, have no plans for pregnancy, sperm donation, or egg donation, and voluntarily take effective contraceptive measures (including the partner, as detailed in Appendix 1). Female participants during the screening period and before the first administration must have a negative pregnancy test result and must be non-lactating.
    • Added---
    • AddedPart of participants with moderate to severe ulcerative colitis:
    • AddedParticipants must meet all of the following criteria to enter this study:
    • AddedParticipants with active ulcerative colitis with a modified 9-point Mayo score of 4 to 9 and an endoscopic item score of 2 to 3, and with a bleeding item score of at least 1.
    • Added---
    • AddedPart of participants with moderate to severe Crohn's disease:
    • AddedParticipants must meet all of the following criteria to enter this study:
    • AddedBaseline CDAI score of 220 to 450, endoscopic SES-CD score (excluding the presence of stenosis) of ≥ 6 points (or isolated ileal disease participants ≥ 4 points), and at least an average daily stool frequency (SF) of 4 timesand/or an average daily abdominal pain (AP) score of ≥ 2 points.
    Exclusion criteria
    • AddedPart 2:
    • AddedParticipants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease) who have any of the following conditions are not eligible to participate in this study (common section):
    • Added1. Medical History or Comorbidities
    • Added1. Participants who have been diagnosed with ulcerative colitis or Crohn's disease and are on the initial treatment (without previous treatment).
    • Added2. During the screening endoscopy, participants have a history of gastrointestinal dysplasia (atypical hyperplasia)/cancer or atypical hyperplasia/cancer. Exclude complete low-grade dysplasia that has been completely removed.
    • Added3. Have evidence of pathogenic intestinal infection. 4. Currently or previously have:
    • AddedHad a major clinical infection (such as requiring hospitalization or parenteral antimicrobial treatment or opportunistic infection) within 1 month before baseline.
    • AddedHad two or more episodes of herpes zoster or disseminated herpes zoster.
    • AddedAny other infection history that the investigator considers may be exacerbated by participating in this study.
    • AddedHad any infection requiring antimicrobial treatment within 2 weeks before screening.
    • Added2. Prior Treatments and Clinical Studies 5. Participants who received azathioprine/6-mercaptopurine, methotrexate, thalidomide treatment within 2 weeks before baseline.
    • Added6. Participants who received cyclosporine, mycophenolate mofetil, tacrolimus or intravenous corticosteroids within 8 weeks before baseline.
    • Added7. Participants who received interferon treatment. 8. Participants who received rectal corticosteroid preparations or 5-ASA treatment within 2 weeks before baseline.
    • Added9. Participants who have participated in any clinical study of drugs (including investigational vaccines) or medical devices within 3 months before baseline or within 5 half-lives (whichever is longer).
    • Added3. Important Medical History or Underlying Diseases Affecting Safety
    • AddedParticipants who have a history of lymphocytic proliferative diseases, including lymphoma or symptoms and signs of potential lymphoproliferative disorders.
    • AddedParticipants who have had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening visit, except for treated skin squamous cell carcinoma or basal cell carcinoma or in situ cervical cancer.
    • AddedParticipants who have had moderate to severe congestive heart failure history (NYHA cardiac function classification ≥ III) within 3 months before screening, or have had cardiovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study.
    • AddedHave active tuberculosis (TB) or latent tuberculosis infection
    • AddedPositive for hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibody (HIV), syphilis antibody test, and anti-hepatitis C virus (HCV) antibody test; if HBsAg is negative, but the hepatitis B core antibody (HBcAb) is positive and the hepatitis B viral deoxyribonucleic acid (HBV DNA) is positive or exceeds the upper limit of the normal value.
    • AddedSuffering from severe, progressive, or uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane (such as severe athlete's foot), and other conditions that the investigator considers not suitable for participation in this trial.

    …and 33 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 2 edited, 3 added
    What changed in the outcomes
    • EditedPart1: Adverse eventsTime frame: From ICF signing date to Day 281
    • EditedPart1: Serious adverse eventsTime frame: From ICF signing date to Day 281
    • AddedPart2: Adverse eventsTime frame: From ICF signing date to Day 393
    • AddedPart2: Serious adverse eventsTime frame: From ICF signing date to Day 393
    • AddedPart2: Results of 12-lead electrocardiographyTime frame: From ICF signing date to Day 393
    Secondary outcomes 8 edited, 9 added
    What changed in the outcomes
    • EditedPart1:Maximum observed concentration of SHR-7590 (Cmax)Time frame: From 0 hour date to Day 281
    • EditedPart1: Time to maximum observed concentration (Tmax) of SHR-7590Time frame: 0 hour to Day 281
    • EditedPart1: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590Time frame: 0 hour to Day 281
    • EditedPart1: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)Time frame: 0 hour to Day 281
    • EditedPart1: Half-life (T1/2) of SHR-7590Time frame: 0 hour to Day 281
    • EditedPart1: Clearance (CL) of SHR-7590Time frame: 0 hour to Day 281
    • EditedPart1: Apparent clearance(CL/F)of SHR-7590Time frame: 0 hour to Day 281
    • EditedPart1: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590Time frame: 0 hour to Day 281
    • AddedPart2: Maximum observed concentration of SHR-7590 (Cmax)Time frame: From 0 hour date to Day 393
    • AddedPart2: Time to maximum observed concentration (Tmax) of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)Time frame: 0 hour to Day 393
    • AddedPart2: Half-life (T1/2) of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Clearance (CL) of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Apparent clearance(CL/F)of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590Time frame: 0 hour to Day 393
    • AddedPart2: Immunogenicity of SHR-7590 in healthy participants and patients with moderate-to-severe ulcerative colitis.Time frame: 0 hour to Day 393
    Interventions Arm changed Dose Level:A→Part1:Dose Level:A; Dose Level:B→Part1:Dose Level:B; Dose Level:C→Part1:Dose Level:C; Dose Level:D→Part1:Dose Level:D; Dose Level:E→Part1:Dose Level:E. Arms added: Part2: Dose Level:A·Part2: Dose Level:B·Part2: Dose Level: C·Part2: Dose Level: D
    + 1 other change: design details
  2. Sep 25, 2026
    Not yet recruiting→Recruiting
    The Second Affiliated Hospital Zhejiang University School of Medicine is now Recruiting
    Enrollment 64→88
    Title A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-Severe Ulcerative Colitissevere Inflammatory Bowel Disease
    + 3 other changes: date precision, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07758101
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Aug 21, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Apr 28, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Si Chen
Contact
si.chen@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion